title: [A case of liver and lung metastases in gastric cancer successfully treated with S-1 and paclitaxel mono-therapy].
abstract: A 65-year-old male underwent a curative distal gastrectomy for advanced gastric cancer in June 2000. S-1 mono- therapy (80 mg/m2, day 1-28/42 days) for liver metastasis in S6 started as the first-line chemotherapy in October 2004. After 3 courses, complete response (CR) was observed for liver metastasis which had continued until January 2007. During the first-line chemotherapy, grade 2 non-hematological toxicities occurred and the S-1 dose reduction was required. Thereafter, no more grade 2 non-hematological toxicities were observed. Paclitaxel mono-therapy (80 mg/m2, day 1, 8, 15/28 days) for multiple lung metastases started as the second-line chemotherapy in February 2007. After 4 courses, complete response (CR) was observed for lung metastasis which has continued until now, May 2008. During the second- line chemotherapy, grade 3 neutropenia and grade 2 leukopenia occurred and a 10% dose reduction of paclitaxel was required three times. Consequently, the hematological toxicities have not occurred.
authors.affiliation: Dept. of Surgery, Sakai Municipal Hospital.
authors.forename: Tomono
authors.initials: T
authors.lastname: Kishimoto
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Imamura
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Furukawa
authors.forename: Yasuhiro
authors.initials: Y
authors.lastname: Miyazaki
authors.forename: Tameyoshi
authors.initials: T
authors.lastname: Yamamoto
authors.forename: Hiroyoshi
authors.initials: H
authors.lastname: Takemoto
authors.forename: Mutsumi
authors.initials: M
authors.lastname: Fukunaga
authors.forename: Hiroki
authors.initials: H
authors.lastname: Ohzato
authors.forename: Masayuki
authors.initials: M
authors.lastname: Tatsuta
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D004338:Drug Combinations; D006801:Humans; D008113:Liver Neoplasms / Q000000981:diagnostic imaging / Q000473:pathology / Q000556:secondary*; D008175:Lung Neoplasms / Q000000981:diagnostic imaging / Q000473:pathology / Q000556:secondary* / Q000601:surgery; D008279:Magnetic Resonance Imaging; D008297:Male; D010094:Oxonic Acid / Q000627:therapeutic use*; D017239:Paclitaxel / Q000627:therapeutic use*; D011859:Radiography; D013274:Stomach Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D005641:Tegafur / Q000627:therapeutic use*
chemical_list: D004338:Drug Combinations; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid; D017239:Paclitaxel